Greenwich LifeSciences, Inc.GLSI

Greenwich LifeSciences, Inc. is burning through its $6.2 million cash pile at an annualised rate of roughly $22.8 million, and the March-2026 10-Q confirms the haemorrhage is accelerating. The company posted a net loss of $5.7 million for the quarter-$5.7 million in red ink on just 14.6 million diluted shares, good for 39 cents of pain per share. Operating loss matched the net loss, and operating cash flow was negative $4.7 million, a quarterly cash burn that would shame a Silicon Valley startup with a “disruptive” app and a ping-pong table.

The company’s core asset is GP2, a HER2-derived peptide immunotherapy designed to coax the patient’s T-cells into recognising and destroying HER2-expressing tumour cells. Greenwich claims four completed clinical trials and has launched a Phase III trial, Flamingo-01, to test whether GLSI-100 can prevent breast cancer recurrence after surgery. The science sounds promising, but the business trail is still a brochure: no revenue, no commercial partnerships, no reimbursement contracts, and no product launch. The company’s website showcases rows of vials and colourful mechanism diagrams, yet the SEC filings contain no product sales, no supply agreements, and no guidance.

Greenwich’s latest SEC filings show total assets of $10.5 million against liabilities of $5.2 million as of March 2026, leaving stockholders’ equity at $5.3 million. Research and development expense for the quarter was $5.2 million, more than the entire cash position. The company’s 10-K for the year ended December 2025 records cash and cash equivalents of $6.2 million, a figure that shrank by $4.7 million in operating cash burn in a single quarter. The board has deferred a chunk of senior-management pay-$367,538 in 2025 alone-but the company’s NT 10-K still flags “substantial doubt” about its ability to continue as a going concern.

Greenwich’s public relations machine keeps chugging: a June 2026 press release trumpets Flamingo-01 Phase III open-label data accepted at ASCO 2026, a milestone that sounds impressive until you notice the filing contains no revenue, no approvals, and no commercialisation plan. The company’s investor site and product pages are glossy enough to impress grant reviewers, but the balance sheet is the real peer review.

For context on the asset class, readers can review the company’s SEC filings directly via the SEC’s EDGAR portal, which hosts the 10-Q, 10-K, NT 10-K, and ownership disclosures. The SEC’s XBRL company facts feed and submissions JSON contain the machine-readable accounting details, but they do not change the human-scale reality: cash is burning, revenue is absent, and the only thing swelling faster than the losses is the board’s deferred-compensation queue.

GLSI’s official materials do their best to maintain a sense of momentum. The product page explains how GP2 works-vaccination, T-cell priming, proliferation, and cancer-cell elimination-while the technology overview promises to “discover the science and innovation within the field of cancer.” Meanwhile, the cash ledger discovers the hard way that discovery does not pay the rent. The company’s SEC filings are the only source of cash and operating facts; everything else is narrative.